Compare · CDIO vs NEOG
CDIO vs NEOG
Side-by-side comparison of Cardio Diagnostics Holdings Inc. (CDIO) and Neogen Corporation (NEOG): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDIO and NEOG operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NEOG is the larger of the two at $2.68B, about 514.3x CDIO ($5.2M).
- NEOG has been more active in the news (17 items in the past 4 weeks vs 4 for CDIO).
- NEOG has more recent analyst coverage (6 ratings vs 0 for CDIO).
- Company
- Cardio Diagnostics Holdings Inc.
- Neogen Corporation
- Price
- -
- -
- Market cap
- $5.2M
- $2.68B
- 1M return
- -
- -7.84%
- 1Y return
- -
- +101.02%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2022
- 1989
- News (4w)
- 4
- 17
- Recent ratings
- 0
- 6
Neogen Corporation
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.
Latest CDIO
- SEC Form 4 filed by Director Betts Wendy J
- SEC Form 4 filed by Director Fung Peter K
- SEC Form 4 filed by Director Intrater James
- SEC Form 4 filed by Director Burton Paul Frederick
- Cardio Diagnostics Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form DEFA14A filed by Cardio Diagnostics Holdings Inc.
- Cardio Diagnostics Report Identifies Growing Rural Cardiovascular Care Gap Amid Ongoing Workforce Shortages and Access Challenges
- Cardio Diagnostics Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Cardio Diagnostics Begins In-House Test Processing at Its New High Complexity CLIA-Certified Laboratory in Iowa City
- SEC Form 10-Q filed by Cardio Diagnostics Holdings Inc.
Latest NEOG
- SEC Form 4 filed by Neogen Corporation
- Neogen Outlines Strategy for Growth, Innovation and Margin Expansion at 2026 Investor Day
- SEC Form 10-Q filed by Neogen Corporation
- SEC Form 8-K filed by Neogen Corporation
- SEC Form 8-K filed by Neogen Corporation
- Neogen Reports First-Quarter Financial Results for Fiscal Year 2027
- Neogen Announces Strategic Collaboration with Hinalea Imaging to Advance Digital Food Safety Solutions
- NEOG Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Neogen (NEOG)
- Director Woteki Catherine E was granted 9,804 units of Restricted Stock Units, increasing direct ownership by 51% to 28,921 units (SEC Form 4)
- Director Wainer Andrea F was granted 9,804 units of Restricted Stock Units, increasing direct ownership by 483% to 11,834 units (SEC Form 4)